IMR multi-bagger?

I’ve been digging into Imricor (ASX:IMR), and the thesis is actually pretty straightforward. It boils down to fixing a massive inefficiency in how heart surgeries, specifically cardiac ablations, are done today. Right now, if you need an ablation (burning small areas of the heart to fix rhythm issues), the doctor guides the catheter using X-rays. This creates two major issues: 1. **Visibility:** X-rays are great for bones, but terrible for soft tissue. Doctors are essentially working with a 2D shadow of the heart. 2. **Radiation:** To do these procedures, medical staff have to wear heavy lead aprons all day, and they still get exposed to radiation. The long-term health risks for these cardiologists are a legitimate industry problem. Imricor has developed the technology to do these procedures inside an MRI machine instead of an X-ray lab. This seems like a no-brainer. MRI provides real-time, 3D visualization of soft tissue (the heart) without any radiation. Doctors can actually see what they are burning while they are doing it, and they can ditch the lead aprons. Usually, when a small cap claims to have "unique tech," I assume a bigger player will just crush them. But Imricor is in a weirdly strong position here and a strong moat. They are currently the only company with certified MRI compatible catheters and hardware. Instead of trying to compete with Imricor, the three biggest MRI manufacturers in the world, GE, Siemens, and Philips have signed agreements to integrate Imricor's tech into their machines. Basically, the hardware giants are providing the razors (the MRI machines), and Imricor is the exclusive provider of the blades (the single-use consumables). They are tackling an $8B+ market that hasn't really changed its core methodology in years. The tech is already proven in Europe, but the big catalyst is the US market. As they move through the FDA process to commercialize in the States, they are transitioning from a "cool science project" to a company with a scalable, recurring revenue model in the world's most lucrative healthcare market. It is rare to find a small cap that has already secured the support of the industry titans before fully scaling. If they execute on the US entry, the valuation gap between where they are now and standard med-tech multiples could close very quickly. Today they announced their FDA approval, and the price is blowing up. TL;DR - IMR going to the moon.